title: [Procedural success and 10-month outcome between Cypher and TAXUS drug-eluting stents for the treatment of in-stent restenosis].
abstract: OBJECTIVE
  To compare the procedural success and 10-month outcome between sirolimus-eluting stent (Cypher stent) and paclitaxel-eluting stent (TAXUS stent) for the treatment of in-stent restenosis lesions.
  
  
  METHODS
  Patients with in-stent restenosis treated with drug-eluting stents (DES) from December 2002 to March 2005 were included in this study and 10 months post stenting follow-up data were reported.
  
  
  RESULTS
  A total of 253 patients with 262 in-stent restenosis lesions were treated with 176 Cypher and 132 TAXUS stents. There were 29 total occlusion, 143 > or = 90% stenosis and 90 < 90% stenosis lesions. Target lesion type distributions were as follows: 9 type A, 45 type B1, 73 type B2 and 135 type C lesions. The mean diameter in Cypher group (2.96 +/- 0.27) mm was smaller than that of TAXUS (3.05 +/- 0.35 mm, P = 0.041) and mean DES length was similar between the two groups (23.31 +/- 6.68 mm vs. 23.56 +/- 6.54 mm, P = 0.745). Procedural success rate of DES implantation was 100% for both Cypher and TAXUS groups. MACE rate during hospitalization was similar between the two groups. At 10-month follow up, MACE rate was significantly higher in TAXUS group than that in Cypher group (16.0% vs. 6.7% P = 0.031) and angiographic in-stent restenosis rate tended also higher in TAXUS group than that in Cypher group (29.4% vs. 14.0%, P = 0.075).
  
  
  CONCLUSIONS
  Procedural success rate was similar between Cypher and TAXUS groups and the angiographic and clinical outcome at 10 months was better in Cypher DES group than in TAXUS DES group.
authors: Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. jilin.chen@263.net
authors: Ji-Lin
authors: JL
authors: Chen
authors: Yue-Jin
authors: YJ
authors: Yang
authors: Shu-Bin
authors: SB
authors: Qiao
authors: Min
authors: M
authors: Yao
authors: Xue-Wen
authors: XW
authors: Qin
authors: Bo
authors: B
authors: Xu
authors: Hai-Bo
authors: HB
authors: Liu
authors: Yong-Jian
authors: YJ
authors: Wu
authors: Jin-Qing
authors: JQ
authors: Yuan
authors: Jue
authors: J
authors: Chen
authors: Shi-Jie
authors: SJ
authors: You
authors: Jun
authors: J
authors: Dai
authors: Jian-Jun
authors: JJ
authors: Li
authors: Run-Lin
authors: RL
authors: Gao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D023903:Coronary Restenosis / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D020123:Sirolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D020123:Sirolimus